Latest news with #LongShortz
Herald Sun
5 days ago
- Business
- Herald Sun
Long Shortz with Caprice Resources: $7M to fund gold exploration in the Murchison
Don't miss out on the headlines from Stockhead. Followed categories will be added to My News. Tylah Tully chats with Caprice Resources (ASX:CRS) CEO Luke Cox after the company raised $7 million dollars to advance exploration at its Murchison gold projects. Plans include RC, aircore and diamond drilling at the Island Gold Project and aircore drilling at the Cuddingwarra Project. A 7,000m drilling program was just completed at Island, with assays expected shortly. Watch the video to learn more. This video was developed in collaboration with Caprice Resources, a Stockhead client at the time of publishing. The interviews and discussions in this video are opinions only and not financial or investment advice. Viewers should obtain independent advice based on their own circumstances before making any financial decisions. Originally published as Long Shortz with Caprice Resources: $7M to fund gold exploration in the Murchison Stockhead Verity Resources is aiming to upgrade and boost resources at its Monument gold project as nearby M&A shines a light on its value. Stockhead Control Bionics is on track for record revenue in FY25 driven by strong performance in the US and growth in Australia.
Mercury
29-05-2025
- Business
- Mercury
Long Shortz: Petratherm
Don't miss out on the headlines from Stockhead. Followed categories will be added to My News. Tylah Tully chats with Petratherm (ASX:PTR) CEO Peter Reid as the company announces its best drilling results to date at the Rosewood prospect, part of the broader Muckanippie project in South Australia. The results extend the mineralisation by 1.6 kilometres and it remains open, pointing to a potentially larger system at play. Watch the video to learn more. This video was developed in collaboration with Petratherm, a Stockhead client at the time of publishing. The interviews and discussions in this video are opinions only and not financial or investment advice. Viewers should obtain independent advice based on their own circumstances before making any financial decisions. Originally published as Long Shortz with Petratherm: Best drilling results to date at Rosewood
Herald Sun
29-05-2025
- Business
- Herald Sun
Long Shortz: Aroa Biosurgery
Tylah Tully chats with Aroa Biosurgery (ASX:ARX) founder and CEO Brian Ward on the company's FY25 results, posting its first profit since listing on the ASX in 2020. The company had a strong year, reporting total revenue of NZ$84.7 million, 23% growth on FY24. In particular, Myriad™ notched just over NZ$32 million in product revenue, 38% growth on the previous financial year. Watch the video to hear Ward's insights. This video was developed in collaboration with Aroa Biosurgery, a Stockhead client at the time of publishing. The interviews and discussions in this video are opinions only and not financial or investment advice. Viewers should obtain independent advice based on their own circumstances before making any financial decisions. Originally published as Long Shortz with Aroa Biosurgery: ARX shears first profit in FY25
Herald Sun
29-05-2025
- Business
- Herald Sun
Long Shortz: Petratherm
Don't miss out on the headlines from Stockhead. Followed categories will be added to My News. Tylah Tully chats with Petratherm (ASX:PTR) CEO Peter Reid as the company announces its best drilling results to date at the Rosewood prospect, part of the broader Muckanippie project in South Australia. The results extend the mineralisation by 1.6 kilometres and it remains open, pointing to a potentially larger system at play. Watch the video to learn more. This video was developed in collaboration with Petratherm, a Stockhead client at the time of publishing. The interviews and discussions in this video are opinions only and not financial or investment advice. Viewers should obtain independent advice based on their own circumstances before making any financial decisions. Originally published as Long Shortz with Petratherm: Best drilling results to date at Rosewood
Mercury
29-05-2025
- Business
- Mercury
Long Shortz: Rhythm Biosciences
Don't miss out on the headlines from Stockhead. Followed categories will be added to My News. Tylah Tully chats with Rhythm Biosciences (ASX:RHY) CEO David Atkins about the company's mission to make cancer a more treatable condition through earlier detection—starting with bowel cancer. Rhythm is developing ColoSTAT, a groundbreaking blood-based diagnostic test designed to detect the likelihood of bowel cancer more easily and effectively than current stool-based methods. He discusses the recent redevelopment of the test, which led to significant improvements in ease of use, cost, speed, and clinical performance. Watch the video to hear more. This video was developed in collaboration with Rhythm Biosciences, a Stockhead client at the time of publishing. The interviews and discussions in this video are opinions only and not financial or investment advice. Viewers should obtain independent advice based on their own circumstances before making any financial decisions. Originally published as Long Shortz with Rhythm Biosciences: Inside ColoSTAT's road to market
